Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Jean Hoffman‐Censits et al.|The Lancet|2016Cited by 3.7k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Joel Picus et al.|New England Journal of Medicine|2015Cited by 2.8k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k